Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cullinan Oncology, Inc.

https://www.cullinanoncology.com/

Latest From Cullinan Oncology, Inc.

Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House

Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.

Deal Watch Business Strategies

Glenmark Follows BeiGene, Nimbus With Early Stage HPK1 Inhibitor

Glenmark is set to initiate a Phase I study for its inhibitor of immuno-oncology target hematopoietic progenitor kinase 1 (HPK1), a segment that has seen increased activity over the recent past with BeiGene, Nimbus and Treadwell Therapeutics among those advancing their molecules.

Research & Development Clinical Trials

5 Dealmaking Trends To Watch In 2022

2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?

Deals Companies

Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space

MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.

Tech Transfer Round-Up Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Cullinan Florentine
    • Cullinan Management, Inc.
    • Cullinan MICA
    • Cullinan Pearl
UsernamePublicRestriction

Register